NCT06698822View on ClinicalTrials.gov

A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA

PHASE2RecruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

October 19, 2026

Study Completion Date

October 19, 2026

Conditions

Cutaneous T-Cell Lymphoma

Interventions

DRUG

tofacitinib 2% cream

Given topical

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER